Clinical value of nifedipine as adjuvant therapy for unstable angina pectoris
Objective:To explore the clinical value of nifedipine as adjuvant therapy combined with clopidogrel for unstable angina pectoris(UAP).Methods:A total of 109 UAP patients admitted to our hospital during May 2021 May 2023 were selected as study subjects.The patients were randomly divided into control group(n=54)and observation group(n=55).Both groups were given conventional treatments such as lipid regulation,and blood pressure lowering.The control group was given aspirin and clopidogrel on top of this,while the observation group was given nifedipine on top of the control group.Both groups were treated for 8 weeks.The clinical efficacy of the two groups was analyzed and compared,as well as the cardiac function,angina attack,coronary microcirculation,and platelet parameters before and after treatment.Results:The total effective rate of treatment in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the stroke volume(SV),left ventricular ejection fraction(LVEF),and cardiac output(CO)in the observation group were significantly higher than those in the control group,while the left ventricular end diastolic diameter(LVEDD),the number and duration of angina attacks were significantly lower than those in the control group(P<0.05).After treatment,the coronary flow reserve(CFR)in the observation group was significantly higher than that in the control group(P<0.05),and the index of microcirculatory resistance(IMR),adenosine diphosphate(ADP)induction,and arachidonic acid(AA)induction were significantly lower than those in the control group(P<0.05).Conclusion:Nifedipine as adjuvant therapy combined with clopidogrel for patients with UAP can improve cardiac function,platelet parameters,coronary microcirculation,alleviate clinical symptoms,and enhance therapeutic efficacy.
NETL
NSTL
万方数据
